

References

S-266

1. Hamstra DA, Mariados N, Sylvester J, et al. Continued benefit to rectal separation for prostate radiation therapy: Final results of a phase III trial. *Int J Radiat Oncol Biol Phys*. 2017;97(5):976-985.
2. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer v2.2021.
3. Schörghofer A, Drerup M, Kunit T, et al. Rectum-spacer related acute toxicity - endoscopy results of 403 prostate cancer patients after implantation of gel or balloon spacers. *Rad Oncol (London, England)*. 2019;14(1):47.
4. Hayes Health Technology Brief. *Absorbable perirectal spacer (Spaceoar System; Augmenix inc.) during radiation therapy for prostate cancer*. Lansdale, PA: Hayes, Inc; 4/10/2021.
5. National Institute for Health and Care Excellence (NICE). Biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer. NICE Interventional Procedure Guidance No. 590. London, UK: National Institute for Health and Care Excellence; 2017. Available at: <https://www.nice.org.uk/guidance/ipg590>. Accessed on May 31, 2019.
6. Fischer-Valuck BW, Chundury A, Gay H, Bosch W, Michalski J. Hydrogel spacer distribution within the perirectal space in patients undergoing radiotherapy for prostate cancer: Impact of spacer symmetry on rectal dose reduction and the clinical consequences of hydrogel infiltration into the rectal wall. *Pract Radiat Oncol*. 2017;7(3):195-202.
7. Miller LE, Efsthathiou JA, Bhattacharyya SK, Payne HA, Woodward E, Pinkawa M. Association of the placement of a perirectal hydrogel spacer with the clinical outcomes of men receiving radiotherapy for prostate cancer: A systematic review and meta-analysis. *JAMA Netw Open*. 2020;1;3(6):e208221.
8. Whalley D, Hruby G, Alfieri F, Kneebone A, Eade T. SpaceOAR Hydrogel in dose-escalated prostate cancer radiotherapy: Rectal dosimetry and late toxicity. *Clin Oncol (R Coll Radiol)*. 2016;28(10):e148-54.
9. Te Velde BL, Westhuyzen J, Awad N, Wood M, Shakespeare TP. Can a peri-rectal hydrogel spaceOAR programme for prostate cancer intensity-modulated radiotherapy be successfully implemented in a regional setting? *J Med Imaging Rad Oncol*. 2017;61(4):528-533.